The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Star Health Insurance is modernising its claims ecosystem to be future-ready
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Subscribe To Our Newsletter & Stay Updated
